Literature DB >> 21370444

Engineering an antiplatelet adhesion layer on an electrospun scaffold using porcine endothelial progenitor cells.

Xing Zhang1, Yuanyuan Xu, Vinoy Thomas, Susan L Bellis, Yogesh K Vohra.   

Abstract

In coronary artery bypass graft interventions, luminal thrombosis is one of the greatest challenges for polymeric grafts with a luminal diameter less than 4 mm. Previously, we reported the fabrication of a highly porous micro/nanofibrous electrospun scaffold and demonstrated the excellent biocompatibility of the scaffolding materials with human endothelial cells. In this study, we explored the engineering of an antithrombotic layer on the scaffold's lumen within 48 h, using peripheral blood-derived porcine endothelial progentior cells (EPC). Flow cytometric results showed that they were CD31(-) but highly CD34(+) and CD105(+) , suggesting the primitive nature of these freshly isolated EPC. The vast majority of EPC readily took up low density lipoprotein, confirming their endothelial phenotype. These EPC also exhibited a strong proliferation capacity on the scaffold for up to 11 days. A confluent layer could be easily engineered within 24 h, which successfully prevented platelet adhesion, a critical step in the cascade of thrombotic events. We concluded that this scaffold could afford a convenient means for the regeneration of a functional cardiovascular endothelium shortly after implantation. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A:, 2011.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21370444     DOI: 10.1002/jbm.a.33040

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  9 in total

Review 1.  Endothelial outgrowth cells: function and performance in vascular grafts.

Authors:  Jeremy J Glynn; Monica T Hinds
Journal:  Tissue Eng Part B Rev       Date:  2013-10-10       Impact factor: 6.389

2.  Association of Leu125Val polymorphisms in the PECAM-1 gene with the risk of coronary heartdisease: a meta-analysis.

Authors:  Tao Xia; Xin Liu; Chang Jiang Du; Xin Jin; Xiang Qian Kong; Gang Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Tri-layered elastomeric scaffolds for engineering heart valve leaflets.

Authors:  Nafiseh Masoumi; Nasim Annabi; Alexander Assmann; Benjamin L Larson; Jesper Hjortnaes; Neslihan Alemdar; Mahshid Kharaziha; Keefe B Manning; John E Mayer; Ali Khademhosseini
Journal:  Biomaterials       Date:  2014-06-16       Impact factor: 12.479

4.  Generation and grafting of tissue-engineered vessels in a mouse model.

Authors:  Mei M Wong; Xuechong Hong; Eirini Karamariti; Yanhua Hu; Qingbo Xu
Journal:  J Vis Exp       Date:  2015-03-18       Impact factor: 1.355

5.  A tissue-engineered subcutaneous pancreatic cancer model for antitumor drug evaluation.

Authors:  Qingyi He; Xiaohui Wang; Xing Zhang; Huifang Han; Baosan Han; Jianzhong Xu; Kanglai Tang; Zhiren Fu; Hao Yin
Journal:  Int J Nanomedicine       Date:  2013-03-19

6.  Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery.

Authors:  Qian Zhan; Baiyong Shen; Xiaxing Deng; Hao Chen; Jiabin Jin; Xing Zhang; Chenghong Peng; Hongwei Li
Journal:  Int J Nanomedicine       Date:  2013-07-11

7.  The therapeutic effect of monocyte chemoattractant protein-1 delivered by an electrospun scaffold for hyperglycemia and nephrotic disorders.

Authors:  Cai Yong; Zhengxin Wang; Xing Zhang; Xiaomin Shi; Zhijia Ni; Hong Fu; Guoshan Ding; Zhiren Fu; Hao Yin
Journal:  Int J Nanomedicine       Date:  2014-02-17

8.  The therapeutic role of monocyte chemoattractant protein-1 in a renal tissue engineering strategy for diabetic patients.

Authors:  Hao Yin; Ming Gao; Lara Leoni; Huifang Han; Xing Zhang; Zhiren Fu
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

9.  A synergistic therapeutic scheme for hyperglycemia and nephrotic disorders in diabetes.

Authors:  Qingyi He; Xing Zhang; Baosan Han; Jianzhong Xu; Kanglai Tang; Zhiren Fu; Hao Yin
Journal:  Theranostics       Date:  2014-03-05       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.